Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.73 |
| ▸ | HPGD | P15428 | 1/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.69 |
| ▸ | TP53 | P04637 | 2/20 | 0.69 |
| ▸ | LMNA | P02545 | 2/20 | 0.69 |
| ▸ | TSHR | P16473 | 2/20 | 0.66 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.66 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | DHODH | Q02127 | 1/20 | 0.63 |
| ▸ | TACR3 | P29371 | 5/20 | 0.62 |
| ▸ | TACR2 | P21452 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | BLM | P54132 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14523182 | 0.94 | LMNA (0.79) | ALDH1A1HPGDKDM4EL3MBTL1TP53 | |
| SCHEMBL14523178 | 0.92 | ALDH1A1 (0.66) | ALDH1A1HPGDKDM4EL3MBTL1TP53 | |
| SCHEMBL5496804 | 0.92 | ALDH1A1 (0.66) | ALDH1A1HPGDKDM4EL3MBTL1TP53 | |
| SCHEMBL6448599 | 0.88 | ALDH1A1 (0.67) | ALDH1A1HPGDKDM4EL3MBTL1TP53 | |
| SCHEMBL16553849 | 0.87 | LMNA (0.67) | ALDH1A1HPGDKDM4EL3MBTL1TP53 | |
| SCHEMBL12564406 | 0.85 | DHODH (0.65) | ALDH1A1HPGDKDM4EL3MBTL1TP53 | |
| SCHEMBL8226622 | 0.85 | ALDH1A1 (0.64) | ALDH1A1HPGDKDM4EL3MBTL1TP53 | |
| SCHEMBL1582049 | 0.84 | ALDH1A1 (0.62) | ALDH1A1HPGDKDM4ETP53LMNA | |
| SCHEMBL15503685 | 0.82 | KDM4E (1.00) | ALDH1A1HPGDKDM4EL3MBTL1TP53 | |
| SCHEMBL26336654 | 0.81 | TACR3 (0.66) | ALDH1A1HPGDKDM4EL3MBTL1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1517708-A1 | COMBINATION TREATMENT FOR DEPRESSION AND ANXIETY BY NK1 AND NK3 ANTAGONISTS | Pfizer Products Inc. (US) | 2005-03-30 | — | — | EP | claimed |
| US-20040006135-A1 | Combination treatment for depression and anxiety | PFIZER INC. | 2004-01-08 | — | — | US | claimed |
| WO-2004000355-A1 | COMBINATION TREATMENT FOR DEPRESSION AND ANXIETY BY NK1 AND NK3 ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2003-12-31 | — | — | WO | claimed |
| EP-1192952-A2 | Combination, for treating depression and anxiety, containing an NK-3 receptor antagonist and a CNS penetrant NK-1 receptor antagonist | Pfizer Products Inc. (US) | 2002-04-03 | — | — | EP | claimed |
| EP-3271015-B1 | NK-3 RECEPTOR ANTAGONISTS FOR THERAPEUTIC OR COSMETIC TREATMENT OF EXCESS BODY FAT | OGEDA S A (BE) | 2023-09-27 | — | — | EP | disclosed |
| US-7208502-B2 | Methods of treating conditions associated with an Edg-3 receptor | MANIV ENERGY CAPITAL (US) | 2007-04-24 | — | — | US | disclosed |
| US-7208502-B2 | Methods of treating conditions associated with an Edg-3 receptor | MANIV ENERGY CAPITAL (US) | 2007-04-24 | — | — | US | disclosed |
| US-20070032459-A1 | METHODS OF TREATING CONDITIONS ASSOCIATED WITH AN EDG-3 RECEPTOR | MANIV ENERGY CAPITAL | 2007-02-08 | — | — | US | disclosed |
| US-20070032459-A1 | METHODS OF TREATING CONDITIONS ASSOCIATED WITH AN EDG-3 RECEPTOR | MANIV ENERGY CAPITAL | 2007-02-08 | — | — | US | disclosed |
| EP-1517708-A1 | COMBINATION TREATMENT FOR DEPRESSION AND ANXIETY BY NK1 AND NK3 ANTAGONISTS | Pfizer Products Inc. (US) | 2005-03-30 | — | — | EP | disclosed |
| US-20040006135-A1 | Combination treatment for depression and anxiety | PFIZER INC. | 2004-01-08 | — | — | US | disclosed |
| WO-2004000355-A1 | COMBINATION TREATMENT FOR DEPRESSION AND ANXIETY BY NK1 AND NK3 ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2003-12-31 | — | — | WO | disclosed |
| EP-1192952-A2 | Combination, for treating depression and anxiety, containing an NK-3 receptor antagonist and a CNS penetrant NK-1 receptor antagonist | Pfizer Products Inc. (US) | 2002-04-03 | — | — | EP | disclosed |
| WO-1996002509-A1 | QUINOLINE DERIVATIVES AS NK3 ANTAGONISTS | SMITHKLINE BEECHAM FARMACEUTICI S.P.A. (IT) | 1996-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006135-A1 | Combination treatment for depression and anxiety | TACR1, NPSR1, HTR3A | ALDH1A1 1132/4885HPGD 2378/4885KDM4E 2767/4885 |
| US-20070032459-A1 | METHODS OF TREATING CONDITIONS ASSOCIATED WITH AN EDG-3 RECEPTOR | EDNRA, EDNRB, ESRRG | ALDH1A1 3227/4885HPGD 660/4885KDM4E 3920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.